Kineta Garners $5,757,742 New Financing Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=f9a49c48-700d-435d-8fd0-7e0fa8812e29&Preview=1 -
Date
8/9/2012 -
Company Name
Kineta -
Mailing Address
219 Terry Ave N Seattle, WA 98109 -
Company Description
Through Kineta, our pioneering team is dedicated to further study of innate immunity with an aggressive strategy to develop early stage programs for powerful new antiviral and immune modulating drugs. We believe our unique approach will yield a new class of drugs to respond to diseases caused by viruses such as, Influenza, Hepatitis C and West Nile virus: diseases that afflict millions of people. -
Website
http://www.kinetabio.com -
Transaction Type
Venture Equity -
Transaction Amount
$5,757,742 -
Transaction Round
Undisclosed -
Proceeds Purposes
Proceeds purposes were not disclosed. SEC regulatory filing. -
M&A Terms
-
Venture Investor
Undisclosed
